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ABSTRACT 
The present research work was to improve the dissolution rate of glipizide which belongs to BCS II drug by enhancing its aqueous 
solubility using different hydrophilic carriers like PEG 6000 and hydroxylpropyl methylcellulose E15 (HPMC E15). The solid 
dispersion was embedded into the matrix of polymers to sustain the release pattern of drug. The various solid dispersion 
formulations were prepared by employing fusion method using different carriers. Further solid dispersion formulations were 
subjected to different in-vitro evaluation tests for solubility, drug content uniformity, drug-polymer interaction, DSC study and in-
vitro drug release study. Tablets were prepared by direct compression method and evaluated for various physical parameters. A 
direct compression method using response surface methodology, followed by optimization of the evaluated parameters was 
employed to get the final optimized formulation. The results of drug content uniformity showed the uniform dispersion of glipizide 
in solid dispersion formulations. The DSC endothermic peak at 216.08°C due to glipizide was partially and completely disappeared 
in solid dispersion formulation indicating that drug was completely dispersed in formulations. In-vitro drug release showed 80.35% 
in 60 minutes for the best solid dispersion formulation S3 (ratio 1:3). Among all the formulations, F4 shows 92.87% better sustained 
release at the end of 12 hrs. The release co-efficient values ‘n’ (˂0.5) indicated that the drug release followed fickian diffusion 
mechanism based on formulation factors. The stability studies were carried out according to ICH guideline and result found of 
selected formulation was stable. 
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INTRODUCTION 
Solid dispersion refers to a group of solid products 
consisting of at least two different compounds, a 
hydrophilic matrix and a hydrophobic drug. The drug 
can be dispersed molecularly, in amorphous particles or 
in crystalline particles. Pharmaceutical polymers are 
used to create this matrix and their selection is based on 
many factors, including physicochemical (drug polymer 
miscibility and stability) and pharmacokinetic (rate of 
absorption) constraints.
1
 In solid dispersions, a portion 
of drug dissolves immediately to saturate the 
gastrointestinal tract fluid, and excess drug precipitates 
as fine colloidal particles or oily globules of submicron 
size. The development of solid dispersions as a 
practically viable method to enhance bioavailability of 
poorly water-soluble drugs overcame the limitations of 
previous approaches such as salt formation, 
solubilization, co-solvency, and particle size reduction.
2
 
An oral route of drug administration is the most 
preferred route of drug delivery due to convenience and 
ease of ingestion. A solid dosage form is a comfortable 
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and familiar means of taking medication. Hence, a 
patient compliance and drug treatment is usually more 
effective with orally administered medications than 
other routes of administration.
3
 The poorly water-
soluble drugs are increasingly becoming a problem in 
terms of obtaining the satisfactory dissolution within the 
gastrointestinal tract that is necessary for 
good bioavailability. Glipizide is an oral hypoglycemic 
agent, which is a commonly prescribed drug for the 
treatment of patients with type II diabetes.
4 
It is used 
adjunct to diet to the management of type II (non-insulin 
dependent) diabetes mellitus in patients whose 
hyperglycemia cannot be controlled by diet and exercise 
alone. Glipizide stimulates insulin secretion from the β 
cells of pancreatic islets tissue, increases the 
concentration of insulin in the pancreatic vein and may 
increase the number of insulin receptors. Glipizide is a 
weak acid (pKa = 5.9) practically insoluble in water and 
acidic environment and highly permeable (class II) 
drugs according to the Biopharmaceutical Classification 
System (BCS).
5
 Glipizide is an oral rapid and short 
acting antidiabetic drug from sulfonylurea class (figure 
1).  
 
Figure 1: 1-cyclohexyl-3-[[p-[2-(5-
methylpyrazinecarboxamido) ethyl] phenyl] sulfonyl] urea 
The oral absorption is uniform, rapid and complete with 
a bioavailability of nearly 100% and an elimination half-
life of 2-4 hours. Glipizide is reported to have a short 
biological half-life (3.4±0.7 h) requiring it to be 
administered in 2 to 3 doses of 2.5 to 10 mg per day. 
Sustained release formulations that would maintain 
plasma levels of drug for 8 to 12 hrs might be sufficient 
for once a day dosing for glipizide. SR products are 
needed for glipizide to prolong its duration of action and 
to improve patient compliance.
6
 Therefore, there is need 
to formulate once daily controlled release tablet of 
glipizide which is convenient for older patients.
7
 The 
hydrophilic polymer selected for the present study was 
hydroxylpropyl methyl cellulose K100 (HPMC K100) 
and xanthan gum. Hydrophilic polymer matrix system 
are widely used for designing oral sustained release 
delivery systems because of their flexibility to provide a 
desirable drug release profile, cost effectiveness, and 
broad regulatory acceptance. HPMC K 100 forms 
transparent tough and flexible films from aqueous 
solution.
8
 So the aim of the proposed work was to 
improve the solubility and dissolution of poorly aqueous 
soluble drug of glipizide which belongs to BCS II using 
solid dispersion technique and to explore the design of 
controlled drug delivery system to prolong the drug 
release in gastrointestinal tract after oral administration. 
MATERIALS AND METHODS 
Materials 
Glipizide was a gift sample from Jash Pharma Pvt. Ltd., 
Mumbai. Polyethylene glycol (PEG 6000), HPMC K-
100 and HPMC E15 was supplied from S.D. Fine 
Chemicals Limited, Mumbai. All the chemicals and 
reagents were used of AR Grade. 
Preparation of solid dispersion by fusion method 
The solid dispersion systems of glipizide were prepared 
with polyethylene glycol (PEG) and hydroxyl propyl 
methyl cellulose (HPMC E15) in 3 different ratios 1:1 
(S1), 1:2 (S2) and 1:3 (S3) by employing fusion method. 
The accurately weighed amount of carrier was melted in 
a porcelain dish and calculated amount of glipizide was 
added with thorough mixing for 1-2 minutes followed 
by solidified rapidly in an ice-bath under vigorous 
stirring. The final solid mass is crushed, pulverized and 
sieved.
6, 9
 
Characterization and evaluation of solid dispersion 
Solubility studies and drug content 
The solubility measurements of glipizide were carried 
out by adding excess amount of drug (50 mg) to 20 ml 
of HPMC E15 and PEG 6000 prepared in phosphate 
buffer of pH 7.4 in a series of stoppered conical flasks in 
the concentration of 2, 4, 6 and 8%. Later, the 
suspensions were agitated at 37°C ± 1°C until 
equilibrium was achieved. Then 1 ml aliquots were 
filtered, diluted suitably and assayed by employing 
Shimadzu UV-Spectrophotometer at 275nm for 
glipizide content. The data were compared with the 
solubility of solid dispersion S1, S2 and S3. The sample 
equivalent to 20 mg of glipizide was accurately weighed 
and transferred to 50 ml volumetric flask and extracted 
in phosphate buffer pH 7.4 using the mechanical shaker. 
The volume was made up to 50 ml with phosphate 
buffer pH 7.4. From this 1ml is subsequently diluted to 
10 ml with phosphate buffer pH 7.4 and assayed for 
glipizide content by measuring at 275 nm using 
phosphate buffer pH 7.4 as blank.  
FT-IR Spectroscopy 
The solid dispersion (S3) was characterized by FT-IR 
spectra by preparing KBr pellets at scanning range of 
4000-400 cm
-1
 using a Shimadzu FT-IR spectrometer.
10 
DSC study 
The physical state of drug in the samples was 
determined by Differential Scanning Calorimetry (DSC) 
using SDTQ 600 V 20.9 BUILD 20, Universal 
V4.5ATA instrument. Samples containing 3 mg of drug 
were placed in the aluminum pans and heated from 10
0
C 
to 350
0
C at a heating rate of 10
0
C/min under inert 
atmosphere flushed with nitrogen at the rate of 20 
ml/min.
11, 12 
Drug dissolution test 
The in-vitro dissolution studies were performed for 
glipizide and all solid dispersion formulations using 
USP XXII dissolution test apparatus type II (Electro lab) 
maintained at 50 rpm. Glipizide pure drug 20mg and 
solid dispersions system equivalent to 20 mg of 
glipizide were accurately weighed and used in each test. 
The dissolution studies were carried out using 900 ml of 
phosphate buffer solutions (pH 7.4), maintained at 37 ± 
5°C was used as dissolution media to maintain the sink 
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condition. The release of glipizide was measured by 
withdrawing 10 ml aliquot samples at regular time 
intervals and withdrawn volume was replaced with fresh 
quantity of dissolution medium.
7, 13
 The withdrawn 
samples were filtered through whattman filter paper and 
suitably diluted with buffer assayed by using Shimadzu 
UV-Spectrophotometer at 275 nm. The % cumulative 
drug release after every time intervals was calculated 
and reported. 
Drug-excipients compatibility studies by Fourier 
Transform Infrared (FTIR) 
Pure drug (glipizide), physical mixtures and solid 
dispersion were examined by Fourier Transform 
Infrared (FT-IR) spectra using potassium bromide pellet 
method. The FTIR spectra were recorded from 4000 to 
400 cm
-1
 in a FTIR Affinity-1(DRS-8000), Shimadzu 
Japan Spectrophotometer.
6
  
Formulation of sustained release matrix tablets of 
glipizide 
The tablets were prepared by direct compression method 
using Rimek Minipress rotary tablet machine to obtain 
the tablets of desired specifications. The solid 
dispersion/polymer mixture ratio prepared by 
homogenously mixing with various concentrations of 
polymers. The compositions of matrices are given in 
table 1. All the ingredients sufficient for a batch of 100 
tablets were weighed and passed through the sieve 40 
(420 mm) and mixed by geometric dilution method and 
finely mixed using polythene bag for proper mixing, 
then prior compression magnesium stearate and talc was 
added as lubricating agent and compressed using a 8 
mm round concave punches in 10 station tablet 
punching machine.  
Factorial design 
The use of trial and error technique for the development 
of a new pharmaceutical formulation leads to a 
satisfactory formulation rather than an optimal one. The 
optimization techniques, on the basis of a few 
experiments and statistical analysis of the results can 
provide an efficient and economical method for the 
prediction of the optimal composition. Design Expert 
7.1 software was used for determining influence of the 
factors on selected responses (table 1). Formulations 
were developed following 3
2 
factorial design after 
setting the individual excipients series of formulations 
mentioned in the table 2 and statistically evaluated the 
effects of two formulation variables viz., the 
concentration of HPMC K100 (X1) and the 
concentration of xanthan gum (X2) on tablet parameters. 
The high and low levels of each variable were coded as 
1 and -1, respectively and the mean value as zero. The 
dependent variables measured were % cumulative drug 
release at 1 hr (Q1), % cumulative drug release after 8 
hrs (Q8) and half life of drug release (t1/2).  
 
Table 1: Level of independent variables for 3
2
 factorial designs 
Independent variables (two) 
Levels (three) 
Low (-1) Medium (0) High (+1) 
Concentration of HPMC K100 (X1) 8 10 12 
Concentration of Xanthan Gum (X2) 7 10 13 
 
Table 2: Formulation components for different batches as per 3
2
 factorial design 
 
Batch 
 
Composition (mg) 
Glipizide solid 
dispersion 
HPMC 
K100 
Xanthan 
gum 
Lactose 
Microcrystalline 
Cellulose 
Magnesium 
Stearate 
Talc 
F1 35 10 5.76 26.24 120 1 2 
F2 35 10 10 22 120 1 2 
F3 35 8 13 21 120 1 2 
F4 35 8 7 27 120 1 2 
F5 35 12 13 17 120 1 2 
F6 35 12.83 10 19.17 120 1 2 
F7 35 10 14.24 17.76 120 1 2 
F8 35 7.17 10 24.83 120 1 2 
F9 35 12 7 23 120 1 2 
 
Stepwise regression analysis was used to find out the 
control factors that significantly affect response 
variables. The results were subjected to ANOVA and 
multiple regression analysis that led to equations 
describing the effect of independent variables on the 
selected responses. The level of significance selected 
was 5 % (P<0.05). Contour plot and response surface 
plot were also conducted and studied. With the help of 
overlay plot best optimized formulation was found out 
by keeping the desired responses. 
Pre-compression parameters 
Pre-compression studies carried out of blend powder 
mixtures for flow properties, bulk density, tapped 
density, compressibility index and Hausner’s ratio.12 
Post-compression parameters 
The formulated matrices were evaluated for thickness, 
hardness, friability, content uniformity, weight variation, 
matrix erosion, swelling index and in-vitro drug release. 
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Thickness and diameter 
Thickness of tablets was determined using Vernier 
caliper. Five tablets from each batch were used, and an 
average value was calculated. Tablet was selected 
random from individual formulation and thickness was 
measured. Tablet thickness should be controlled within a 
± 5% variation of slandered value.  
Weight variation, hardness and friability 
Weight variation, friability test was conducted according 
to USP and the hardness was measured with Monsanto 
hardness tester.
6, 12 
Content uniformity 
Randomly ten tablets were weighed and powdered. A 
quantity equivalent to 20 mg of glipizide was placed in 
100 ml volumetric flask and dissolved in phosphate 
buffer pH 7.4 solutions, sonicated for 5 minutes and 
made up the volume up to the mark and filtered through 
membrane filter. After appropriate dilutions, the drug 
content was determined by UV spectrophotometer at 275 
nm against suitable blank using standard plot equation.
14
 
In-vitro release study 
The in-vitro release study for all the formulations were 
carried out for 12 hrs using a USP-Dissolution Test 
Apparatus Type-II (USP Dissolution Apparatus IP/USP, 
Veego Scientific DA6D, Mumbai) using  900 ml of  7.4 
pH phosphate buffer at 37±0.5ºC with paddle rotation 
speed of 50 rpm.  At predetermined intervals 10 ml 
sample was withdrawn and equal volume was replaced 
to maintain sink condition. The sample was further 
diluted with corresponding media and absorbance 
measured in a UV spectrophotometer (Pharma Spec UV- 
1700; Shimadzu, Japan) at 275 nm against suitable 
blank. The absorbance was converted to drug 
concentration using a calibration curve (Abs = 
0.034xConc + 0.05; R
2
 = 0.993) and then cumulative % 
drug released was calculated with the help of dilution 
factor.
14
 
Analysis of in-vitro drug release kinetics and 
mechanism 
To describe the kinetics and % releases of the drug 
release from sustain release matrix glipizide formulation. 
The drug release data from factorial batches were fitted 
in to various kinetic release mathematical models such 
as zero order, first order, Higuchi, Korsmeyer-Peppas 
models by using PCP-Disso-v3 software. The regression 
coefficient (r
2
) value compared to each other and 
selected best fit model, the release mechanism of 
glipizide from system were decided from release 
exponent value. The zero-order kinetic describes the 
system in which the drug release rate is independent of 
its concentration. The first order kinetic describes the 
system in which the drug release rate is concentration 
dependent. Higuchi describe the release of drug from an 
insoluble matrix as square root of time dependent 
process. The Hixon-Crowell cube root law describes the 
drug release from system in which there is change in the 
surface area and the diameter of particles present in 
dosage form.
15, 16
 
 Zero order Kinetics    Q = K0t 
 First order Kinetics    Log C = Log C0-Kt/2 
 Higuchi’s Square root of time Equation( Diffusion 
model)                        Q = Kt
½
 
 Hixon-Crowell cube root Equation (Erosion model) 
                          (100-W) 
1/3
 = 100
1/3
 – k3t 
 Korsmeyer-Peppas model Equation (Diffusion/ 
Relaxation Model) 
             Mt/M0 = k5t
n
 
Stability Study 
The optimized formulation was subjected to stability at 
40 ±2
0
C and 75 ± 5 % RH for period of six months. 
After three and end of month tablet sample was analyzed 
for physical characteristics and drug release profile.
17 
RESULT AND DISCUSSION 
Solubility of pure drug was determined in water which 
was then compared with the solubility of solid 
dispersion S1, S2 and S3. The effect of PEG 6000 and 
HPMC E15on the solubility of glipizide was studied and 
results summarized in table 3.  
 
Table 3: Solubility and drug content in solid dispersion of glipizide 
Formulation 
Solubility Drug content 
Concentration (%) Solubility (mg/ml) Concentration (mg/ml) Drug Content (%) 
Drug 
1 0.23 0.025 4.41 
2 0.26 0.25 26.52 
3 0.29 0.5 47.26 
S1 (1:1) 
1 2.02 1.0 68.97 
2 3.52 0.025 5.88 
3 7.05 0.25 28.79 
S2 (1:2) 
1 4.08 0.5 50.91 
2 7.82 1.0 88.52 
3 11.26 0.025 9.71 
S3 (1:3) 
1 8.79 0.25 30.47 
2 13.41 0.5 57.85 
3 15.05 1.0 110.67 
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The solubility studies showed that solubility of glipizide 
increased with concentrations of carrier. From the 
solubility and drug content analysis, sustained release 
solid dispersion (1:3) was selected for further studies. 
Fourier-transform infrared (FT-IR) spectroscopy was 
used to characterize possible interactions between the 
drug and the carrier in solid state. The IR spectra of 
solid dispersion and polymers used in solid dispersion 
are compared with the standard spectrum of glipizide. 
To study the possible interactions between glipizide, 
PEG 6000 and HPMC E15, FT-IR spectra of solid 
dispersions was compared with the drug alone. The FT-
IR spectra of glipizide exhibit characteristic peaks at 
3352.64 cm
−1
 (NH stretching), 1482.99 cm
−1
 (C=O 
stretching), 1649.8 cm
−1
 (NH bending), 1333.53 cm
−1
 
(sulphonamide), 1307.5 cm
−1
 (aromatic), 1159.97 cm
−1 
(sulphone). In the FT-IR spectra of the best solid 
dispersion formulation S3, C=O and S=O stretching of 
sulphonyl group of the glipizide was shifted towards 
higher wavelength and the other peaks are almost the 
same (figure 2).  
 
 
Figure 2: FTIR spectrum of glipizide and solid dispersion 
 
Figure 3: DSC Thermo grams of (a) glipizide, (b) PEG 6000, (c) HPMC E15, (d) Solid dispersion 
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This indicated that overall symmetry of the molecule is 
not significantly affected. The shift in the peaks 
associated with the glipizide indicates an increase in 
bond strength, possibly due to the stabilizing effect of 
the hydrogen atoms of PEG or may be due to the 
intermolecular hydrogen bonding between glipizide and 
PEG in the solid state. 
DSC studies were carried out for more confirmation for 
the difference in crystallinity of glipizide and DSC 
thermogram are shown in figure 3. It showed that an 
endothermic peak of glipizide could be detected at about 
216.08 ºC, PEG 6000 at 66.63 ºC, HPMC E15 at 60.96 
and solid dispersion at 62.59 ºC. The best solid 
dispersion S3 in the ratio of 1:3 prepared using fusion 
method shows sharp endothermic peak at 60.96°C which 
could be due to the melting point of HPMC E15. The 
endothermic peak of glipizide is suppressed indicating 
glipizide would completely disperse in polymer. The 
disappearance of glipizide peak indicates decrease in 
crystallinity. This may explain the best enhancement of 
glipizide dissolution and hence confirms the formulation 
of solid dispersion. 
Drug-excipients interaction studies 
Fourier-transform infrared spectra were obtained by an 
FTIR-Affinity-1 spectrophotometer using the KBr disc 
method for determination of drug and polymer 
compatibility study. FTIR spectrum of pure glipizide 
showed characteristic peaks at 3352.64 cm
−1
 (NH 
stretching), 1482.99 cm
−1
 (C=O stretching), 1649.8 cm
−1
 
(NH bending), 1333.53 cm
−1
 (sulphonamide), 1307.5 
cm
−1
 (aromatic), 1159.97 cm
−1 
(sulphone).  In FTIR 
spectrum of HPMC K100, peaks were observed at 1240 
cm
−1
 (ether) and 2922 cm
−1
 due to CH stretching. FTIR 
spectrum of PEG showed peaks at 1124 cm
−1
 (ether), 
3450 cm
−1
 (OH stretching H bonded). FTIR spectrum of 
xanthan gum showed characteristic peaks at 3435 cm
−1
 
(alcoholic OH stretching free), 2886 cm
−1
 for presence 
of alkane, 1690 cm
−1
 indicating the presence of 
unsaturated carboxylic acid. FTIR spectra of powder 
blend showed peaks at 1649 cm
−1
 (NH bending), 1333 
cm
−1
 (sulphonamide), 1307 cm
−1
 (aromatic), 1240 cm
−1
 
(ether), 1023 cm
−1
 (alcoholic OH bending), 1124 cm
−1
 
(ether), 3435 cm
−1
 (alcoholic OH stretching free), 2886 
cm
−1
 (alkane) and 1690 cm
−1
 (unsaturated carboxylic 
acid). From the results (figure 4) obtained from FTIR 
spectra it was concluded that spectrum of physical 
mixture of glipizide shows that all the bands of glipizide 
in physical mixtures were preserved and shows no 
interaction in physical mixtures.  
 
 
 
Figure 4: FT-IR spectrum for compatibility study of glipizide and polymers 
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The bulk and tapped density of blend powder were 
found to be in the range of 0.31 – 0.33 and 0.39 – 0.46, 
respectively (table 4). Carr’s compressibility index and 
hausner ratio are determined to be less than 16.83% and 
<1.49 for all formulations respectively, which indicates 
that the powder blend of all the formulations have fair to 
good flow property.  The physical properties of tablets 
like hardness, friability, thickness, diameter, drug 
content and weight variation were found to be within 
limits indicating that the prepared matrix tablets met the 
USP specifications (table 5). The formulation showed 
hardness value in the range of to 5.8 to 7.16 Kg/cm
2
. 
The friability value for all tablet formulation were found 
to be less than 1% indicate that the friability within the 
prescribed limit.  
 
Table 4: Pre-compression powder characteristics of F1-F9 batches 
Parameters F1 F2 F3 F4 F5 F6 F7 F8 F9 
Angle of repose 23 ± 
1.852 
24 ± 
1.331 
23 ± 
1.537 
24 ± 
2.961 
22 ± 
1.321 
21 ± 
1.525 
22 ± 
1.532 
27 ± 
1.862 
21 ± 
1.267 
Bulk density 0.32 ± 
0.01 
0.31 ± 
0.11 
0.32 ± 
0.02 
0.31 ± 
0.04 
0.32 ± 
0.14 
0.33 ± 
0.02 
0.33 ± 
0.11 
0.32 ± 
0.12 
0.31 ± 
0.24 
Tapped density 0.44 ± 
0.023 
0.45 ± 
0.008 
0.39± 
0.004 
0.44 ± 
0.009 
0.42 ± 
0.006 
0.41 ± 
0.043 
0.46± 
0.004 
0.42 ± 
0.005 
0.46 ± 
0.011 
Compressibility 
index 
11.16 ± 
1.24 
11.57 ± 
1.41 
12.82 ± 
1.22 
10.68 ± 
1.22 
13 ± 
1.03 
12.99 ± 
1.51 
11.42 ± 
1.64 
14.19 ± 
1.54 
16.83 ± 
1.60 
Hausner’s ratio 1.13 ± 
0.06 
1.09 ± 
0.03 
1.13 ± 
0.04 
1.19 ± 
0.07 
1.16 ± 
0.05 
1.20 ± 
0.02 
1.14 ± 
0.01 
1.49 ± 
0.06 
1.11 ± 
0.03 
 (± Standard deviation, n = 3) 
Table 5: In process quality control (IPQC) test for batches F1-F9 
Parameters F1 F2 F3 F4 F5 F6 F7 F8 F9 
Hardness 
(Kg/cm
2
) 
6.02 ± 
0.06 
5.80 ± 
0.45 
5.97 ± 
0.14 
6.89 ± 
0.11 
6.26 ± 
0.12 
7.16 ± 
0.37 
6.14 ± 
0.13 
5.76 ± 
0.27 
6.19 ± 
0.11 
Weight 
uniformity (mg) 
201 ± 
0.54 
194.9 ± 
0.13 
200 ± 
0.78 
202± 
0.13 
196 ± 
0.14 
204 ± 
0.37 
200 ± 
0.59 
191 ± 
0.5 
190 ± 
0.14 
Diameter (mm) 
8.02 ± 
0.01 
8.02 ± 
0.03 
8.01 ± 
0.06 
8.02 ± 
0.02 
8.01 ± 
0.03 
8.01 ± 
0.02 
8.03 ± 
0.01 
8.01 ± 
0.05 
8.04 ± 
0.04 
Thickness (mm) 
2.30 ± 
0.01 
2.30 ± 
0.01 
2.32 ± 
0.01 
2.32 ± 
0.03 
2.12 ± 
0.03 
2.33 ± 
0.01 
2.31 ± 
0.01 
2.21 ± 
0.01 
2.33 ± 
0.01 
Friability (%) 
0.79 ± 
0.09 
0.61 ± 
0.21 
0.77 ± 
0.10 
0.75 ± 
0.04 
0.53 ± 
0.08 
0.72 ± 
0.1 
0.58 ± 
0.02 
0.68 ± 
0.25 
0.62 ± 
0.16 
Drug Content 
Uniformity (%) 
103.9 ± 
1.47 
99.5 ± 
2.14 
103.6 
± 0.14 
98.5 ± 
1.32 
101 ± 
1.32 
103 ± 
2.58 
98 ± 
0.11 
101.3 ± 
2.12 
101.0 ± 
2.17 
 
The pharmacopoeial limits of deviation for tablets of 
200 mg are ± 7.5 % i.e. ± 11.25mg. The average 
percentage deviation for all tablet formulation was 
found to be within the specified limits and hence all 
formulation complied with the test for uniformity of 
weight. Uniformity of all drug content was found within 
and among the ranged from 100.5 % to 103.6 %. In-
vitro dissolution studies of solid dispersions were 
compared with the pure glipizide. It was found that the 
drug dissolution was highest i.e., 85.35% in the 
formulation S3 (drug and carrier ratio was 1:3 prepared 
by employing fusion method at the end of 60 minutes. 
Formulations containing solid dispersion in combination 
with XNG and HPMC K100 were compared to explore 
the effect of polymers and the amount of the drug 
release. The glipizide was released about 100% within 8 
hrs from batches F5 to F9. Percent of drug release at the 
end of 10 hrs for F1, F2, F3, F5 and F6 were 
90.05±0.3%, 99.18±0.3%, 96.43±0.4%, 93.55±0.13% 
and 97.80±0.3% respectively. In the matrices 
formulation, HPMC K100 and XNG were used as 
prolonged and retard release polymer. These polymers 
produce gel-forming matrices and in contact with gastric 
fluid, possess sufficient structure to form a gel layer. 
The release pattern of all formulation is depicted in 
figure 5. 
The all factorial formulation batches were subjected to 
various release models, by using PCP-Disso-V3 
Software. The four batches F1, F2, F6 and F9 showed 
Hixon Crowell as best fit model. F3, F4, F5 and F7 
showed Korsmeyer- Peppas  as best fit model  and only 
F8 showed Quadratic Model as best fit model. By using 
Korsmeyer - Peppas equation, the value n was obtained. 
This value is characteristics of Anomalous kinetics (non 
fickian transport) for F1, F7, F8 and characteristics of 
fickian diffusion for F2, F3, F4, F5 (table 6). 
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Figure 5: Dissolution studies of matrix formulation 
 
Statistical formulation optimization by 3
2 
factorial 
design 
It was observed that % drug release after 1 hour and 
after 8 hours ranging from 20 % to 45%, 88% to 100 % 
respectively and half life of drug release (t50) ranging 
from 5 hrs to 10 hrs. The wide variation indicated that 
the physical properties of glipizide tablets were 
significantly influenced by the combinations of 
independent variables (table 7).  
 
Table 6: Model fitting of factorial batches 
Code 
Higuchi 
Model 
Hixon- Crowell 
Model 
Quadratic 
Model 
Korsmeyer Peppas 
Model 
 
 
 
Best fit model 
R R R R 
Release 
Exponent(n) 
F1 0.9862 0.9921 0.9912 0.9870 0.572 Hixon- Crowell 
F2 0.9729 0.9973 0.9869 0.9828 0.381 Hixon- Crowell 
F3 0.9789 0.9822 0.9783 0.9862 0.385 Korsmeyer- Peppas 
F4 0.9938 0.9786 0.9726 0.9967 0.415 Korsmeyer- Peppas 
F5 0.9746 0.9777 0.9750 0.9808 0.391 Korsmeyer – Peppas 
F6 0.9821 0.9956 0.9946 0.9840 0.449 Hixon- Crowell 
F7 0.8390 0.8317 0.8315 0.8404 0.571 Korsmeyer- Peppas 
F8 0.9815 0.9888 0.9905 0.9816 0.539 Quadratic 
F9 0.9805 0.9888 0.9876 0.9844 0420 Hixon- Crowell 
 
Table 7: Effect of factors on responses variables of glipizide matrices 
Formulation code 
X1 X2 Y1 Y2 Y3 
Conc. of 
HPMC K100 
Conc. of 
Xanthan Gum 
% cumulative drug 
release at 1 hr (Q1) 
% cumulative drug 
release after 8 hrs (Q8) 
t50 
F1 10 5.76 20 88.82 5.17 
F2 10 10 30 94.11 7 
F3 8 13 44.17 95.68 10.19 
F4 8 7 41 88.20 9.36 
F5 12 13 45.88 95.68 10.82 
F6 12.83 10 31.76 97.64 7.37 
F7 10 14.24 23.52 91.76 5.92 
F8 7.17 10 22.94 98.82 5.68 
F9 12 7 37.05 100.01 8.45 
 
ANOVA for model with responses using 5 % 
significance level is represented in table 8. From the 
results, it can be concluded that for all three responses, 
the cross-product (interaction X1X2) effect and quadratic 
effect (X1
2
, X2
2
) are not significant. But the linear (X1-
HPMC K100, X2-XG) model terms are significant. The 
polynomial equation contains coefficient for intercept, 
regression coefficients, individual effects (X1 and X2); 
quadratic effects (X1
2
 and X2
2
); the interaction effect 
(X1X2). The sign and magnitude of the main effects 
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signify the relative influence of each factor on the 
responses (table 8). The equation in terms of coded 
factors can be used to make predictions about the 
response for given levels of each factor. By default, the 
high levels of the factors are coded as +1 and the low 
levels of the factors are coded as -1. The coded equation 
is useful for identifying the relative impact of the factors 
by comparing the factor coefficients. The equation in 
terms of actual factors can be used to make predictions 
about the response for given levels of each factor. This 
equation should not be used to determine the relative 
impact of each factor, because the coefficients are scaled 
to accommodate the units of each factor and the 
intercept is not at the center of the design space. 
 
% cumulative drug release at 1 hr (Y1) = 1.84 + 0.117X1 + 0.684X2 -0.025X1X2 + 0.15X1
2 + 0.45X2
2 
% cumulative drug release after 8 hrs (Y2) = 5.52 + 0.54 X1 + 1.07 X2 + 0.15 X1X2 + 0.44 X1
2 -0.17 X2
2 
t50 (Y3) = 10.83 + 1.07 X1 + 2.37 X2 -0.5 X1X2 + 0.77 X1
2 + 0.067 X22 
Table 8: ANOVA for model with responses 
Source 
Y1 Y2 Y3 
F 
Value 
p-value 
Prob> F 
F 
Value 
p-value 
Prob> F 
F 
Value 
p-value 
Prob> F 
Model 40.41 0.00593 20.34 0.017 20.058 0.017 
A-HPMC K100 38.083 0.0086 16.29 0.028 8.64 0.061 
B-Xanthan Gum 152.34 0.00115 80.16 0.00294 86.76 0.0027 
AB 2.0083 0.252 2.386 0.23 0.598 0.496 
A
2
 8.39 0.063 2.81 0.193 0.482 0.538 
B
2
 1.24 0.347 0.022 0.894 3.825 0.146 
P* = < 0.05 indicate significant model terms 
 
Figure 6 and 7 shows linear correlation between actual 
and predicted values for % cumulative drug release at 1 
hr and % cumulative drug release after 8 hrs 
respectively.  From this graph we can conclude that 
factorial design used for optimization was valid with 
some error in predicted and actual values. Contour Plot 
for the relationship between amount of HPMC K100 and 
xanthan gum on t50 shows non-linear effect of amount of 
polymer HPMC K100 and xanthan gum (figure 8). The 
results showed  that as the concentration of HPMC K100 
and xanthan gum increases, % drug release decreases 
showing controlled release of drug from the prepared 
formulation while polymer concentration increases, half 
life (t50) of drug increases. 
 
Figure 6: Contour Plot for the relationship between 
amount of HPMC K100 and xanthan gum on % 
cumulative drug release at 1 hr (Y1) 
 
Figure 7: Contour Plot for the relationship between 
amount of HPMC K100 and xanthan gum on % 
cumulative drug release after 8 hrs (Y2) 
 
Figure 8: Contour Plot for the relationship between 
amount of HPMC K100 and xanthan gum on t50 (Y3) 
Design-Expert® Software
Q1
Design Points
45.88
20
X1 = A: conc of HPMC
X2 = B: Conc of XG
8.00 9.00 10.00 11.00 12.00
7.00
8.50
10.00
11.50
13.00
Q1
A: conc of  HPMC
B
: C
o
n
c 
o
f 
X
G
31.8454
33.0245
34.2036
35.3827
36.5618
Design-Expert® Software
Q8
Design Points
100.58
88.2
X1 = A: conc of HPMC
X2 = B: Conc of XG
8.00 9.00 10.00 11.00 12.00
7.00
8.50
10.00
11.50
13.00
Q8
A: conc of  HPMC
B
: C
o
n
c 
o
f X
G
90.6592
92.4545
94.2498 96.0452
96.0452
97.8405
97.8405
Design-Expert® Software
t50
Design Points
10.82
5.17
X1 = A: conc of HPMC
X2 = B: Conc of XG
8.00 9.00 10.00 11.00 12.00
7.00
8.50
10.00
11.50
13.00
t50
A: conc of  HPMC
B
: 
C
o
n
c
 o
f 
X
G
7.42536
7.73123
8.03709
8.34295
8.64881
 Shende et al                                                                                                          Journal of Drug Delivery & Therapeutics. 2017; 7(6):38-48                        
ISSN: 2250-1177                                                                              [47]                                                                            CODEN (USA): JDDTAO 
The formulation with an appropriate controlled release 
profile and 90% drug release over a 6–12 hours period 
was desired for the purpose of this study. Therefore, 
formulation F4 was considered most suitable and found 
desired region during optimization by overlay plot for 
the extended matrices. The extended retardation of drug 
release observed with xanthan gum may be attributed to 
the three dimensional gel network structure developed 
by polymer following penetration of dissolution medium 
into the tablet matrix. An incorporation of xanthan gum 
along with HPMC K100 decreased the release rate of 
drug because the polymer absorbs water and forms a 
gelatinous barrier layer at the surface of the tablet 
matrix. Usually, water diffusivity depends on the total 
concentration of viscosity-inducing agents in a system 
and this governs diffusion of water into matrix 
systems.
18 
The optimized F4 formulation showed good 
controlled release for longer time periods, good physical 
properties of matrices, Korsmeyer- Peppas as best fit 
model with 0.415 release exponent for  fickian diffusion 
mechanism than the other formulations (figure 9). The 
simplicity of the formulation, ease of manufacturing and 
complete dissolution of drug from system is among the 
advantages of the developed matrix formulations. The 
results of release studies indicated the possibility of 
achieving a suitable modulation of matrix release rate by 
opportunely varying ratio of matrix tablets. 
 
Figure 9: Model fitting of release profile for optimized 
F4 formulation 
Statistical analysis of the results, before and after 
conducting the stability studies for 6 months, was carried 
out using paired students t-test. No significant difference 
(p> 0.05) was observed in the tablet appearance, 
hardness or thickness. The drug dissolution profile was 
compared of before and after stability studies. The 
optimized formulation (F4) values were found more than 
50 (91.26 and 90.15 respectively after one and three 
months) that indicate a good similarity between both the 
dissolution profiles. Similarly, no significant difference 
was observed in the post formulation parameter. The 
stability studies showed that there was no significant 
change in dissolution profile after storage. 
CONCLUSION 
With findings of research, it would be noticed that PEG 
6000 and HPMC E15 in the best solid dispersion S3 has 
characteristics to form molecular dispersions with the 
drug molecules, hence enhancing the dissolution rate of 
drug and decreasing the time of drug release from the 
solid dispersion. The glipizide sustained release 
formulation (F4) with HPMC K100 (8 mg) and xanthan 
gum (7 mg) showed good controlled release for longer 
time periods, good physical properties of matrices and 
exhibited less percentage deviation of response 
parameters from both predicted and target responses in 
comparison to other predicted formulations. The 
mechanism of release of glipizide from matrices was 
following Korsmeyer-Peppas as well as fickian 
diffusion. The results of stability studies for 
formulations F4 revealed no change in physical 
appearance, hardness and drug indicating the 
formulation was stable. From the present study, it can be 
concluded that glipizide matrices could be developed 
with desirable release modulation by solid dispersion 
sustained release matrix tablets for a once daily 
administration. 
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